For Quick Alerts
For Daily Alerts

Glenmark Pharma Rallies 9% On DCGI Approval For Covid 19 Trial


Shares of Glenmark Pharmaceuticals in intra-day trade on April 30, 2020 rallied a whopping 9% as it became the first company to receive the Drug Controller General of India (DCGI) approval for conducting trials of tablets for treatment against Covid 19 patients.

Glenmark Pharma Rallies 9% On DCGI Approval For Covid 19 Trial

On both the stock exchanges it rallied to a high of Rs. 359 per share.

The company by itself developed the active pharmaceutical ingredients (API) as well as the formulations for the product and filed for the approval by the DGCI and received the regulators nod for conducting trial of the tablet on mild to moderate patients of the virus.

Favipiravir antiviral tablet has shown results against influenza viruses and has been approved in Japan for treating novel influenza virus infections, it added.

Last at 2:06 pm, the stock quoted higher by 4.16% or Rs. 13.7 at Rs. 343.40. The stock's 52-week high price is Rs. 653.60 per share.

Read more about: glenmark pharmaceuticals dcgi
Story first published: Thursday, April 30, 2020, 14:22 [IST]
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more